Speakers:
As the Biden administration transitions into the White House, life sciences companies and investors must navigate new forces on the horizon, including the potential for legal and regulatory action on drug pricing and more aggressive antitrust enforcement.
Please join us for a discussion on recent and probable developments in drug pricing and antitrust emanating from Washington, D.C., their potential impact on life sciences strategic and private equity transactions, and how to anticipate and mitigate their potential impact.
Presenters
Stay Up To Date with Ropes & Gray
Subscribe to Our Podcast
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Follow Us on Social
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
Join Our Mailing List
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.